INT143499

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.02
First Reported 2007
Last Reported 2007
Negated 0
Speculated 0
Reported most in Abstract
Documents 1
Total Number 1
Disease Relevance 0.32
Pain Relevance 0.59

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (Gldc) lyase activity (Gldc) oxidoreductase activity (Gldc)
enzyme binding (Gldc) cellular amino acid metabolic process (Gldc)
Gldc (Mus musculus)
Pain Link Frequency Relevance Heat
antagonist 4 100.00 Very High Very High Very High
nMDA receptor 4 99.68 Very High Very High Very High
nMDA receptor antagonist 1 95.52 Very High Very High Very High
Morphine 1 91.00 High High
agonist 1 71.92 Quite High
intrathecal 1 68.84 Quite High
substance P 2 68.80 Quite High
Spinal cord 1 51.52 Quite High
Pain 3 25.00 Low Low
nociceptor 3 25.00 Low Low
Disease Link Frequency Relevance Heat
Nociception 5 97.46 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The nociceptive behavior was also dose-dependently inhibited by i.t. co-administration of 7-chlorokynurenic acid (0.25-4 nmol), a competitive antagonist of the glycine recognition site on the NMDA receptor ion-channel complex; D-(-)-2-amino-5-phosphonovaleric acid (62.5-500 pmol), a competitive NMDA receptor antagonist; MK-801 (62.5-500 pmol), an NMDA ion-channel blocker; ifenprodil (0.5-8 nmol); arcaine (31-125 pmol); and agmatine (0.1-10 pmol), all being antagonists of the polyamine recognition site on the NMDA receptor ion-channel complex.
Negative_regulation (antagonist) of glycine recognition site associated with nociception, nmda receptor antagonist, nmda receptor and antagonist
1) Confidence 0.02 Published 2007 Journal J. Pharmacol. Sci. Section Abstract Doc Link 17452810 Disease Relevance 0.32 Pain Relevance 0.59

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox